Serum
amyloid A1 (SAA1) is an inflammatory associated
high-density lipoprotein. And It is also considered as a predictor and prognostic marker of
cancer risk. However, its role and mechanisms in
glioblastoma (GBM) still unclear. In this study, we validate that SAA1 is up-regulated in GBM, and its high expression predicts poor prognosis. SAA1 knockdown promotes the apoptosis of GBM cell. Mechanistically, SAA1 knockdown can inhibit
serine/threonine protein kinase B (AKT) phosphorylation, thereby regulating the expression of apoptosis-related
proteins such as Bcl2 and Bax, leading to GBM cell death. Moreover,
Gliomas with low SAA1 expression have increased sensitivity to
Temozolomide (TMZ). Low SAA1 expression segregated
glioma patients who were treated with
Temozolomide (TMZ) or with high MGMT promoter methylation into survival groups in TCGA and CGGA dataset. Our study strongly suggested that SAA1 was a regulator of cells apoptosis and acted not only as a prognostic marker but also a novel
biomarker of sensitivity of
glioma to TMZ.